• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Monday, July 6, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Technology from a Mount Sinai startup wins NYC Life Science Innovation Showcase

Bioengineer by Bioengineer
July 18, 2017
in Health
Reading Time: 3 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram
IMAGE

Credit: Mount Sinai Innovation Partners

Technology for identifying at-risk atrial fibrillation (AFib) patients was chosen as the winner of the inaugural Alexandria LaunchLabs Scholarship Award, which recognizes excellence in health care technology, entrepreneurship and business competencies. The technology, developed by a Mount Sinai researcher and entrepreneur, Ya-El Mandel-Portnoy, PhD, was selected from entries submitted by 26 of New York City's top academic entrepreneurs, who presented their work to investors and biopharma business executives at the 2017 NYC Life Science Innovation Showcase on June 13, 2017.

Dr. Mandel-Portnoy launched Cardea Sciences, a startup addressing the critical unmet medical need of effectively stratifying patients with AFib–the most common cardiac arrhythmia, costing the United States an estimated $26 billion annually–during her doctorate program at the Icahn School of Medicine at Mount Sinai. Her winning technology will help patients and care providers to better manage AFib in an outpatient setting by measuring pulse deficit–the difference in the heart rate between key areas in the body–and segmenting AFib patients based on the magnitude of their pulse deficit.

"Cardea Sciences' focus is on patient outcomes, empowering patients and clinicians to manage the disease by identifying those AFib patients who will not tolerate the arrhythmia well and will suffer from severe adverse events," said Dr. Mandel-Portnoy. "This will help care providers optimize their course of treatment and reduce the number of readmissions, thus leading to a reduction in health care costs."

As the Alexandria LaunchLabs Scholarship Award winner, Dr. Mandel-Portnoy will receive laboratory and office space at the innovative Alexandria LaunchLabs, New York City's premier, full-service life science startup platform at the Alexandria Center for Life Science – New York City.

"Dr. Mandel-Portnoy is a product of the innovation ecosystem that we've built at Mount Sinai. We are thrilled that Cardea Sciences was recognized by Alexandria LaunchLabs and look forward to its success," said Erik Lium, PhD, Senior Vice President of Mount Sinai Innovation Partners, the commercialization arm of the Icahn School of Medicine at Mount Sinai.

The NYC Life Science Innovation Showcase was organized by Alexandria Real Estate Equities, Inc., an urban office REIT focused on collaborative life science and technology campuses, in partnership with the New York Academic Consortium.

"We are thrilled to have Dr. Mandel-Portnoy bring her passion and excitement for entrepreneurship to the Alexandria LaunchLabs community and are committed to helping her build a successful company around her promising AFib technology," said Blake Stevens, PhD, general manager of Alexandria LaunchLabs.

###

About Mount Sinai Innovation Partners (MSIP)

MSIP is responsible for driving the real-world application and commercialization of Mount Sinai discoveries and the development of research partnerships with industry. The aim is to translate these innovations into healthcare products and services that benefit patients and society. MSIP is responsible for the full spectrum of commercialization activities required to bring the Icahn School of Medicine and the Mount Sinai Health System's inventions to life. These activities include evaluating, patenting, marketing and licensing new technologies, engaging commercial and non-profit relationships for sponsored research, material transfer and confidentiality, as well as fostering an ecosystem of entrepreneurship within our research and health system communities. For more information, visit http://www.ip.mountsinai.org.

About Alexandria LaunchLabs at the Alexandria Center for Life Science – New York City

Alexandria LaunchLabs is New York City's premier, full-service startup platform designed to satisfy key unmet needs for plug-and-play space and strategic risk capital for seed- and early-stage life science companies in New York City. Located at the Alexandria Center for Life Science – New York City, Alexandria LaunchLabs provides move-in-ready office/laboratory space, first-class support resources, shared equipment and services, creative amenities and access to startup capital through the Alexandria Seed Capital Platform–all of which are critical for accelerating the growth of seed- and early-stage companies in New York City. The Alexandria LaunchLabs team continues to accept applications for future members. For more information, please visit http://www.launchlabsnyc.com.

Media Contact

Cynthia Cleto
[email protected]
646-605-7359
@mountsinainyc

http://www.mountsinai.org

Share12Tweet8Share2ShareShareShare2

Related Posts

Flame retardant BDE-209 targets molecularly linked to ulcerative colitis

July 6, 2026

Kidney transplant outcomes in older adults studied by German researchers

July 6, 2026

Salmonella protein SopB curbs early inflammation to slow disease progression

July 6, 2026

Multi-metal cooperation drives lung cancer chemoresistance, reversed by MiADMSA

July 6, 2026
Please login to join discussion

POPULAR NEWS

  • Detection of EDCs in Breast Milk and Infant Urine Up to Six Months Highlights Early Exposure Risks

    77 shares
    Share 31 Tweet 19
  • New Drug Candidate Developed at McMaster Shows Potential for Treating Brain Cancer

    58 shares
    Share 23 Tweet 15
  • Saying Goodbye to PGY-6: Pediatric Fellowship Realities

    103 shares
    Share 41 Tweet 26
  • KTU Researchers Explore Ultrasound’s Role in Enhancing Blood Flow Beyond Diagnostics

    53 shares
    Share 21 Tweet 13

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Flame retardant BDE-209 targets molecularly linked to ulcerative colitis

Ultra-high frequency particle impacts mimic rockbursts to shatter hard rock

Kidney transplant outcomes in older adults studied by German researchers

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 83 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.